ShareThis Page
John Dorfman

CVS and Gilead Sciences hit the Casualty List

John Dorfman
| Monday, Jan. 15, 2018, 11:00 p.m.
A CVS Pharmacy in Pittsburgh.
Gene J. Puskar/AP
A CVS Pharmacy in Pittsburgh.

Starving in the midst of plenty, some stocks got roughed up in the fourth quarter even as the market rose.

Four of these stocks — CVS Inc., Gilead Sciences Inc., Owens & Minor Inc. and Argan Inc. — are on my Casualty List. It's a roster I compile quarterly, containing stocks that have been wounded and that I think will recover.

This is the 59th Casualty List I've published since mid-2000. The average one-year gain on recommendations from the first 55 lists has been 19 percent, compared with 9.9 percent for the Standard & Poor's 500 Index.

Of the 55 lists, 39 were profitable, and 32 beat the S&P 500.

The Casualty List from one year ago did particularly well, returning 52.3 percent — versus 25.7 percent for the S&P 500 — from January 17, 2017, through January 12, 2018.

Myriad Genetics Inc. (MYGN) spearheaded the advance with a 128 percent gain. Also moving up sharply were Akorn Inc. (AKRX), with a 58 percent return, and PVH Corp. (PVH), up 52 percent. My other pick, Hibbett Sports Inc. (HIBB), fell 28 percent.

Bear in mind that my column recommendations are theoretical and don't reflect actual trades, trading costs or taxes. Their results shouldn't be confused with the performance of portfolios I manage for clients. And past performance doesn't predict future results.


Since the S&P 500 was up 6.64 percent in the fourth quarter, I looked for casualties among stocks that were down more than 10 percent, or more than 16 points worse than the overall market.

One that I like is CVS (symbol CVS), down 11 percent in the quarter. CVS a few years ago was a conventional drugstore chain, selling general merchandise (including cigarettes) along with health products and prescriptions. Today, the company devotes more space to health-related items, has ditched the cigarettes and is trying to merge with Aetna Inc. (AET), a big health insurer.

Given the increasing creakiness of my (baby boom) generation, and the health consciousness of younger generations, I think CVS is well positioned. The stock sells for 15 times earnings in a market where the average stock fetches 23.


I've been wrongly bullish on Gilead Sciences (GILD) in the past, but now that it has dropped 11 percent in the fourth quarter and sells for less than nine times earnings, I must say I find it attractive again.

This is, after all, a company that has grown its book value (corporate net worth per share) at more than 28 percent a year over the past decade. It's a very profitable company, with a return on stockholders' equity of about 55 percent in the past four quarters.

There are also negatives to Gilead. Revenue and earnings fell in 2017, and analysts expect another decline in 2018. Debt is almost 140 percent of stockholders' equity. Sales of its leading hepatitis C drug have slowed way down as competition increases.

The big question for Gilead, as for many biotech firms, is whether the public, insurers and the government will continue to accept king-sized prices on new and promising drugs. Certainly, there is political pressure to keep these prices down, and President Trump has been among those urging price cuts.

On balance though, I like the risk-reward ratio here.

Owens & Minor

Only seven Wall Street analysts cover Owens & Minor (OMI), and not one recommends it. They are split between “hold” and “sell” ratings.

This friendless stock, which sold for about $35 a share at the end of 2016, now goes for about $21. It plunged about 35 percent in the fourth quarter. The company, based in Mechanicsville, Va., distributes medical and surgical supplies.

Are things really so bleak? Analysts predict $2.20 per share in earnings this year, which would be a record. And they expect 2019 to be better. If their estimates are right, the stock is selling for only about nine times 2018 earnings.


Argan (AGX) builds powers plants, primarily natural-gas-fueled ones. It could benefit from the long-term trend for gas power-generation facilities to replace coal-fired plants.

Growth the past few years has been excellent. However, the pipeline of future projects is skimpy, and management in a recent call hinted that there may be no near-term solution to that problem.

That was enough for investors to slam Argan for a 33 percent loss in the fourth quarter. I think the decline is a bit of an overreaction. And there are two things I like about the stock: It carries a 2.2 percent dividend yield, and the company is debt-free.

Disclosure: I own Argan, Gilead Sciences and Myriad Genetics for some of my clients. At present, I don't own them personally.

John Dorfman is chairman of Dorfman Value Investments LLC in Newton Upper Falls, Mass., and a syndicated columnist. His firm or clients may own or trade securities discussed in this column. He can be reached at

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me